New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTSTEM, CUR, OSIR, ASTM, BTX, GERNSupreme Court turns down appeal over stem cell research, SCOTUSblog says
The Supreme Court turned down an appeal by scientists seeking to stop all studies on embryonic stem cells, according to SCOTUSblog. The Fly notes that companies engaged in the research, development, and commercialization of stem cell therapies include StemCells (STEM), Neuralstem (CUR), Aastrom Biosciences (ASTM) and Osiris Therapeutics (OSIR). Also, earlier this morning, BioTime (BTX) entered into an agreement to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's (GERN) human embryonic stem cell programs. Reference Link
News For STEM;CUR;OSIR;ASTM;BTX;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
16:08 EDTASTMGreat Point Partners reports 9.99% passive stake in Aastrom
Subscribe for More Information
15:43 EDTASTMStonepine Capital reports 7.1% passive stake in Aastrom
09:19 EDTCURNeuralstem ALS investigator presents long-term follow up Phase I data
Neuralstem announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up data on the Phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis, or ALS. The presentation, which occurred at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal, Canada, on Friday, and was not open to the public, covered data up to approximately 1200 days post the stem cell treatment. Dr. Glass reported that patients in the last safety cohort, who received treatments in both the lumbar and the cervical region with the highest number of cells per injection, all showed significant slowing of the progression of the disease. One patient showed functional improvement from pre-treatment baseline, which is maintained to present day. The other two patients are maintaining the same level of functionality as they had at the baseline for over three years since the stem cell treatment. "The long-term follow up data is very encouraging," said Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "In Phase I, patients 10, 11, and 12 each received 10 lumbar and five cervical injections, of 100,000 cells each, which was far below the safe maximal dose. Even so, the data shows a significant slowing of the disease progression for over three years. If replicated on a larger scale, this could represent meaningful improvement in quality of life, and lifespan, compared to untreated patients. In our Phase II dose escalation trial, we successfully reached the maximal dose planned, which consisted of 20 lumbar and 20 cervical injections of 400,000 cells each, more than ten times the number of stem cells delivered in the highest dose cohort of the Phase I trial."
September 19, 2014
09:04 EDTBTXBioTime unit presents PanC-Dx data
Subscribe for More Information
September 17, 2014
09:04 EDTBTXBioTime unit receives OpRegen preclinical safety and efficacy study results
BioTime, HBL Hadasit Bio-Holdings and Cell Cure Neurosciences announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its development-stage product designated OpRegen, which is intended for use in the treatment of dry form age-related macular degeneration. These studies were conducted by Cell Cure and contract research organizations in preparation for an IND filing with the Food and Drug Administration for a Phase 1/2a study in patients with geographic atrophy, the severe stage of dry-AMD. OpRegen is intended to be administered into the subretinal space of patients as a suspension of cells to treat this leading cause of blindness. The company said, "The protection of the animal’s vision from decay was dose dependent. As an additional indicator of therapeutic potential, the number of cone photoreceptors, which are responsible for fine vision in humans and are degenerating in the macula of dry-AMD patients, was found to remain constant over an extended period in the animal model.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use